The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Dissecting Fragment-Based Lead Discovery at the von Hippel-Lindau Protein:Hypoxia Inducible Factor 1α Protein-Protein Interface
Open accessAbstract
SUMMARY Fragment screening is widely used to identify attractive starting points for drug design. However, its potential and limitations to assess the tractability of often challenging protein:protein interfaces have been underexplored. Here, we address this question by means of a systematic deconstruction of lead-like inhibitors of the pVHL:HIF-1α interaction into their component fragments. Using biophysical techniques commonly employed for screening, we could only detect binding of fragments that violate the Rule of Three, are more complex than those typically screened against classical druggable targets, and occupy two adjacent binding subsites at the interface rather than just one. Analyses based on ligand and group lipophilicity efficiency of anchored fragments were applied to dissect the individual subsites and probe for binding hot spots. The implications of our findings for targeting protein interfaces by fragment-based approaches are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 1×
“There is increasing evidence that these features render a PPI more ligandable than, for example, obligate PPIs involving large and flat interfaces (Surade and Blundell, 2012), and that these types of PPIs are providing new therapeutic opportunities (Filippakopoulos et al., 2010).”
BackgroundThe influence of drug-like concepts on decision-making in medicinal chemistry
Leeson, P. D., & Springthorpe, B. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2445 · Cited by 2,403
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
Min, J.-H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.1073440 · Cited by 765
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., Fauber, B. P., Pan, B., Malek, S., Stokoe, D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116510109 · Cited by 618
Buckley, D. L., Van Molle, I., Gareiss, P. C., Tae, H. S., Michel, J., Noblin, D. J., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja209924v · Cited by 569
Self-citationDiscovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation
Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490
Site-directed ligand discovery
Erlanson, D. A., Braisted, A. C., Raphael, D. R., Randal, M., Stroud, R. M., Gordon, E. M., & Wells, J. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.17.9367 · Cited by 466
Structural Biology and Drug Discovery of Difficult Targets: The Limits of Ligandability
Surade, S., & Blundell, T. L. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.12.013 · Cited by 230
Research works printed but not linked: 41
- Babaoglu, 2006, Deconstructing fragment-based inhibitor discovery, Nat. Chem. Biol., 2, 720, 10.1038/nchembio831 · DOI · Paper page
- Barelier, 2010, Fragment-based deconstruction of Bcl-xL inhibitors, J. Med. Chem., 53, 2577, 10.1021/jm100009z · DOI
- Basse, 2010, Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant, Chem. Biol., 17, 46, 10.1016/j.chembiol.2009.12.011 · DOI · Paper page
- Braisted, 2003, Discovery of a potent small molecule IL-2 inhibitor through fragment assembly, J. Am. Chem. Soc., 125, 3714, 10.1021/ja034247i · DOI · Paper page
- Ciulli, 2007, Fragment-based approaches to enzyme inhibition, Curr. Opin. Biotechnol., 18, 489, 10.1016/j.copbio.2007.09.003 · DOI
- Ciulli, 2006, Probing hot spots at protein-ligand binding sites: a fragment-based approach using biophysical methods, J. Med. Chem., 49, 4992, 10.1021/jm060490r · DOI
- Congreve, 2003, A ‘rule of three’ for fragment-based lead discovery?, Drug Discov. Today, 8, 876, 10.1016/S1359-6446(03)02831-9 · DOI · Paper page
- Congreve, 2008, Recent developments in fragment-based drug discovery, J. Med. Chem., 51, 3661, 10.1021/jm8000373 · DOI · Paper page
- Coyne, 2010, Drugging challenging targets using fragment-based approaches, Curr. Opin. Chem. Biol., 14, 299, 10.1016/j.cbpa.2010.02.010 · DOI
- Crews, 2010, Targeting the undruggable proteome: the small molecules of my dreams, Chem. Biol., 17, 551, 10.1016/j.chembiol.2010.05.011 · DOI · Paper page
- Dalvit, 2001, WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability, J. Biomol. NMR, 21, 349, 10.1023/A:1013302231549 · DOI · Paper page
- Edfeldt, 2011, Fragment screening to predict druggability (ligandability) and lead discovery success, Drug Discov. Today, 16, 284, 10.1016/j.drudis.2011.02.002 · DOI · Paper page
- Erlanson, 2004, Fragment-based drug discovery, J. Med. Chem., 47, 3463, 10.1021/jm040031v · DOI · Paper page
- Fauman, 2011, Structure-based druggability assessment—identifying suitable targets for small molecule therapeutics, Curr. Opin. Chem. Biol., 15, 463, 10.1016/j.cbpa.2011.05.020 · DOI · Paper page
- Hajduk, 2007, A decade of fragment-based drug design: strategic advances and lessons learned, Nat. Rev. Drug Discov., 6, 211, 10.1038/nrd2220 · DOI · Paper page
- Hajduk, 2005, Druggability indices for protein targets derived from NMR-based screening data, J. Med. Chem., 48, 2518, 10.1021/jm049131r · DOI · Paper page
- Hajduk, 2011, Drug discovery: A question of library design, Nature, 470, 42, 10.1038/470042a · DOI
- Higueruelo, 2009, Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database, Chem. Biol. Drug Des., 74, 457, 10.1111/j.1747-0285.2009.00889.x · DOI
- Hopkins, 2004, Ligand efficiency: a useful metric for lead selection, Drug Discov. Today, 9, 430, 10.1016/S1359-6446(04)03069-7 · DOI · Paper page
- Kaelin, 2008, The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer, Nat. Rev. Cancer, 8, 865, 10.1038/nrc2502 · DOI · Paper page
- Kozakov, 2011, Structural conservation of druggable hot spots in protein-protein interfaces, Proc. Natl. Acad. Sci. USA, 108, 13528, 10.1073/pnas.1101835108 · DOI · Paper page
- Köster, 2011, A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes, J. Med. Chem., 54, 7784, 10.1021/jm200642w · DOI
- Kranz, 2011, Protein thermal shifts to identify low molecular weight fragments, Methods Enzymol., 493, 277, 10.1016/B978-0-12-381274-2.00011-X · DOI
- Larsson, 2011, Efficiency of hit generation and structural characterization in fragment-based ligand discovery, Curr. Opin. Chem. Biol., 15, 482, 10.1016/j.cbpa.2011.06.008 · DOI
- Loenarz, 2009, Evidence for a stereoelectronic effect in human oxygen sensing, Angew. Chem. Int. Edit. Engl., 48, 1784, 10.1002/anie.200805427 · DOI
- Lundquist, 2002, The cluster glycoside effect, Chem. Rev., 102, 555, 10.1021/cr000418f · DOI · Paper page
- Mayer, 1999, Characterization of ligand binding by saturation transfer difference NMR spectroscopy, Angew. Chem. Int. Edit. Engl., 38, 1784, 10.1002/(SICI)1521-3773(19990614)38:12<1784::AID-ANIE1784>3.0.CO;2-Q · DOI · Paper page
- Mortenson, 2011, Assessing the lipophilicity of fragments and early hits, J. Comput. Aided Mol. Des., 25, 663, 10.1007/s10822-011-9435-z · DOI
- Murray, 2002, The consequences of translational and rotational entropy lost by small molecules on binding to proteins, J. Comput. Aided Mol. Des., 16, 741, 10.1023/A:1022446720849 · DOI · Paper page
- Murray, 2009, The rise of fragment-based drug discovery, Nat. Chem., 1, 187, 10.1038/nchem.217 · DOI · Paper page
- Murray, 2012, Experiences in fragment-based drug discovery, Trends Pharmacol. Sci., 33, 224, 10.1016/j.tips.2012.02.006 · DOI · Paper page
- Nazaré, 2012, Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes, Angew. Chem. Int. Edit. Engl., 51, 905, 10.1002/anie.201107091 · DOI
- Page, 1971, Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect, Proc. Natl. Acad. Sci. USA, 68, 1678, 10.1073/pnas.68.8.1678 · DOI · Paper page
- Petros, 2006, Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis, J. Med. Chem., 49, 656, 10.1021/jm0507532 · DOI · Paper page
- Saxty, 2007, Identification of inhibitors of protein kinase B using fragment-based lead discovery, J. Med. Chem., 50, 2293, 10.1021/jm070091b · DOI
- Stout, 1998, The additivity of substrate fragments in enzyme-ligand binding, Structure, 6, 839, 10.1016/S0969-2126(98)00086-0 · DOI
- Śledź, 2011, From crystal packing to molecular recognition: prediction and discovery of a binding site on the surface of polo-like kinase 1, Angew. Chem. Int. Edit. Engl., 50, 4003, 10.1002/anie.201008019 · DOI
- Teotico, 2009, Docking for fragment inhibitors of AmpC beta-lactamase, Proc. Natl. Acad. Sci. USA, 106, 7455, 10.1073/pnas.0813029106 · DOI
- Tsao, 2006, Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design, Bioorg. Med. Chem., 14, 7953, 10.1016/j.bmc.2006.07.050 · DOI
- Wells, 2007, Reaching for high-hanging fruit in drug discovery at protein-protein interfaces, Nature, 450, 1001, 10.1038/nature06526 · DOI · Paper page
- Yin, 2005, Strategies for targeting protein-protein interactions with synthetic agents, Angew. Chem. Int. Edit. Engl., 44, 4130, 10.1002/anie.200461786 · DOI · Paper page
Cited by
Induced protein degradation: an emerging drug discovery paradigm
Lai, A. C., & Crews, C. M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.211 · Cited by 1,486
Self-citationNatural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery
Thomford, N. E., Senthebane, D. A., Rowe, A., Munro, D., Seele, P., Maroyi, A., & Dzobo, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061578 · Cited by 1,241
Small molecules, big targets: drug discovery faces the protein–protein interaction challenge
Scott, D. E., Bayly, A. R., Abell, C., & Skidmore, J. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.29 · Cited by 1,137
PROTACs: past, present and future
Li, K., & Crews, C. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00193d · Cited by 869
Self-citationPROteolysis TArgeting Chimeras (PROTACs) — Past, present and future
Pettersson, M., & Crews, C. M. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.01.002 · Cited by 800
Self-citationSmall‐Molecule PROTACS: New Approaches to Protein Degradation
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201507978 · Cited by 674
Self-citationPROTACs: great opportunities for academia and industry
Sun, X., Gao, H., Yang, Y., He, M., Wu, Y., Song, Y., Tong, Y., & Rao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0101-6 · Cited by 613
Targeted protein degradation: elements of PROTAC design
Paiva, S.-L., & Crews, C. M. (2019) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.02.022 · Cited by 576
Self-citationBAF complex vulnerabilities in cancer demonstrated via structure-based PROTAC design
Farnaby, W., Koegl, M., Roy, M. J., Whitworth, C., Diers, E., Trainor, N., Zollman, D., Steurer, S., Karolyi-Oezguer, J., Riedmueller, C., et al. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0294-6 · Cited by 562
Self-citationModulators of Protein–Protein Interactions
Milroy, L.-G., Grossmann, T. N., Hennig, S., Brunsveld, L., & Ottmann, C. (2014) · Chemical Reviews · doi:10.1021/cr400698c · Cited by 497
HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins
Buckley, D. L., Raina, K., Darricarrere, N., Hines, J., Gustafson, J. L., Smith, I. E., Miah, A. H., Harling, J. D., & Crews, C. M. (2015) · ACS Chemical Biology · doi:10.1021/acschembio.5b00442 · Cited by 488
Self-citationProtac-Induced Protein Degradation in Drug Discovery: Breaking the Rules or Just Making New Ones?
Churcher, I. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01272 · Cited by 491
Targeted Protein Degradation: from Chemical Biology to Drug Discovery
Cromm, P. M., & Crews, C. M. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.024 · Cited by 412
Self-citationGaldeano, C., Gadd, M. S., Soares, P., Scaffidi, S., Van Molle, I., Birced, I., Hewitt, S., Dias, D. M., & Ciulli, A. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5011258 · Cited by 399
Self-citationE3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones
Ishida, T., & Ciulli, A. (2021) · SLAS Discovery · doi:10.1177/2472555220965528 · Cited by 380
Self-citationZoppi, V., Hughes, S. J., Maniaci, C., Testa, A., Gmaschitz, T., Wieshofer, C., Koegl, M., Riching, K. M., Daniels, D. L., Spallarossa, A., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01413 · Cited by 336
Self-citationDegradation of proteins by PROTACs and other strategies
Wang, Y., Jiang, X., Feng, F., Liu, W., & Sun, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.001 · Cited by 335
Chemistries of bifunctional PROTAC degraders
Cao, C., He, M., Wang, L., He, Y., & Rao, Y. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00220e · Cited by 313
Small‐Molecule Inhibitors of the Interaction between the E3 Ligase VHL and HIF1α
Buckley, D. L., Gustafson, J. L., Van Molle, I., Roth, A. G., Tae, H. S., Gareiss, P. C., Jorgensen, W. L., Ciulli, A., & Crews, C. M. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206231 · Cited by 302
Self-citationA small molecule HIF-1α stabilizer that accelerates diabetic wound healing
Li, G., Ko, C.-N., Li, D., Yang, C., Wang, W., Yang, G.-J., Di Primo, C., Wong, V. K. W., Xiang, Y., Lin, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23448-7 · Cited by 261
Maniaci, C., Hughes, S. J., Testa, A., Chen, W., Lamont, D. J., Rocha, S., Alessi, D. R., Romeo, R., & Ciulli, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00954-1 · Cited by 245
Self-citationHughes, S. J., & Ciulli, A. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170041 · Cited by 240
Self-citationBulatov, E., & Ciulli, A. (2015) · Biochemical Journal · doi:10.1042/bj20141450 · Cited by 237
Self-citationTrivalent PROTACs enhance protein degradation via combined avidity and cooperativity
Imaide, S., Riching, K. M., Makukhin, N., Vetma, V., Whitworth, C., Hughes, S. J., Trainor, N., Mahan, S. D., Murphy, N., Cowan, A. D., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00878-4 · Cited by 251
Self-citationRecent Developments in PROTAC‐Mediated Protein Degradation: From Bench to Clinic
Hu, Z., & Crews, C. M. (2022) · ChemBioChem · doi:10.1002/cbic.202100270 · Cited by 231
Self-citationPRosettaC: Rosetta Based Modeling of PROTAC Mediated Ternary Complexes
Zaidman, D., Prilusky, J., & London, N. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.0c00589 · Cited by 224
Targeted protein degradation via intramolecular bivalent glues
Hsia, O., Hinterndorfer, M., Cowan, A. D., Iso, K., Ishida, T., Sundaramoorthy, R., Nakasone, M. A., Imrichova, H., Schätz, C., Rukavina, A., et al. (2024) · Nature · doi:10.1038/s41586-024-07089-6 · Cited by 222
Self-citationTargeted Protein Degradation by Small Molecules
Bondeson, D. P., & Crews, C. M. (2017) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103507 · Cited by 207
Self-citationSystematic Targeting of Protein–Protein Interactions
Modell, A. E., Blosser, S. L., & Arora, P. S. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.05.008 · Cited by 184
Harnessing the Power of Proteolysis for Targeted Protein Inactivation
Verma, R., Mohl, D., & Deshaies, R. J. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.010 · Cited by 185
State-of-the-art strategies for targeting protein–protein interactions by small-molecule inhibitors
Sheng, C., Dong, G., Miao, Z., Zhang, W., & Wang, W. (2015) · Chemical Society Reviews · doi:10.1039/c5cs00252d · Cited by 165
Mutant-selective degradation by BRAF-targeting PROTACs
Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications · doi:10.1038/s41467-021-21159-7 · Cited by 152
Self-citationAmide-to-Ester Substitution as a Strategy for Optimizing PROTAC Permeability and Cellular Activity
Klein, V. G., Bond, A. G., Craigon, C., Lokey, R. S., & Ciulli, A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01496 · Cited by 152
Self-citationFunctional E3 ligase hotspots and resistance mechanisms to small-molecule degraders
Hanzl, A., Casement, R., Imrichova, H., Hughes, S. J., Barone, E., Testa, A., Bauer, S., Wright, J., Brand, M., Ciulli, A., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-022-01177-2 · Cited by 133
Self-citationHypoxia inducible factor (HIF) as a model for studying inhibition of protein–protein interactions
Burslem, G. M., Kyle, H. F., Nelson, A., Edwards, T. A., & Wilson, A. J. (2017) · Chemical Science · doi:10.1039/c7sc00388a · Cited by 39
Niedermolekulare PROTACs: neue Wege zum Abbau von Proteinen
Toure, M., & Crews, C. M. (2016) · Angewandte Chemie · doi:10.1002/ange.201507978 · Cited by 40
Self-citationA small-molecule VHL molecular glue degrader for cysteine dioxygenase 1
Tutter, A., Buckley, D., Golosov, A. A., Ma, X., Shu, W., McKay, D. J. J., Darsigny, V., Dovala, D., Beckwith, R., Solomon, J., et al. (2025) · Nature Chemical Biology · doi:10.1038/s41589-025-01936-x · Cited by 36
Self-citation
Metadata
- Authors
- Van Molle, I., Thomann, A., Buckley, D. L., So, E. C., Lang, S., Crews, C. M., & Ciulli, A.
- Venue
- Chemistry & Biology
- Publisher
- Elsevier BV
- Published
- 2012-10
- Volume
- 19
- Issue
- 10
- Pages
- 1300-1312
- ISSN
- 1074-5521 (ISSN-L)
- OpenAlex
- W2065136554
- Cited by
- 188
- References
- 11
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 390 d)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.